1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Innova Captab Limited

Innova Captab Limited

INNOVACAP.NS
Innova Captab LimitedIN flagNational Stock Exchange of India
990.85
INR
+8.00
- -
56.70BMarket Cap
Innova Captab Limited
INNOVACAP.NS
(National Stock Exchange of India)

Recent

price

990.85

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
86.25
94.6
71.57
139.76
161.71
212.99
215.71
280.28
284.77
Revenue per Share
6.11
8.49
6.03
11.18
11.87
18.66
22.41
24.63
24.62
Basic EPS, GAAP
1.88
4.64
3.99
-3.67
-2.07
-27.89
-18.99
8.42
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
2
- -
Dividend per Share
2.1
2.1
25.3
36.45
48.31
75.53
89.2
111.9
111.87
Book Value per Share
2.31
10.34
25.23
33.46
45.27
160.85
164.61
187.44
187.39
Tangible Book Value per Share
57
57
57
57
57
51
57
57
57
Basic Weighted Avg Shares
4,936
5,413
4,096
7,998
9,254
10,770
12,344
16,039
16,300
Sales/Revenue/Turnover
10.94
13.17
12
11.09
11.36
13.14
13.4
11.67
11.86
Operating Margin (%)
107
101
56
75
111
160
248
452
452
Depreciation Expense
350
486
345
640
680
943
1,283
1,409
1,409
Net Income, GAAP
27.16
28.34
25.56
25.39
25.97
27.16
25
25.15
25.15
Effective Tax Rate (%)
7.08
8.98
8.42
8
7.34
8.76
10.39
8.79
8.65
Profit Margin (%)
-555
-161
553
845
1,649
3,143
3,501
4,284
4,284
Working Capital
271
127
64
679
1,356
2,105
2,449
2,158
2,158
LT Debt
305
763
1,448
2,086
2,765
8,309
9,594
10,908
10,908
Total Equity
- -
39.05
21.95
22.15
16.93
13
10.45
10.23
10.56
Return on Invested Capital (%)
- -
60.22
27.66
22.71
17.8
19.25
17.61
16.74
16.76
Return on Capital (%)
- -
404.91
44.01
36.2
28.02
28.66
28.75
24.49
24.49
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
1,060
- -
1,279
LT Borrowings
2,294
- -
2,148
LT Finance Leases
10
- -
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
57
- -
57
Market Capitalization
48,833
41,206
39,487

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
8,141
- -
9,230
Cash, Cash Equivalents & STI
1,073
- -
445
Accounts Receivable, Net
3,949
- -
4,373
Inventories
2,358
- -
2,833
Total Current Liabilities
4,134
- -
4,946
Payables & Accruals
- -
- -
- -
ST Debt
1,060
- -
1,279
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
61.25%
13.69%
Free Cash Flow
- -
137.13%
-144.33%
Net Income, GAAP
- -
35.26%
9.87%
Sales/Revenue/Turnover
- -
34.38%
29.93%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,332
2,829
3,025
2,583
10,770
2025
2,943
3,182
3,165
3,147
12,344
2026
3,515
3,804
4,503
4,478
16,039

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3.07
4
4.39
- -
18.66
2025
5.15
6.12
5.97
5.17
22.41
2026
5.42
5.18
7.37
6.65
24.63

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
2
Similar Companies
Atlas Energy Corp. (CANSF)
CF PharmTech, Inc. (2652.HK)
Ecofibre Limited (EOF.AX)
Blau Farmacêutica S.A. (BLAU3.SA)
Filament Health Corp. (FLHLF)
Coenzyme-A Inc. (PPII)
Business
Innova Captab Limited, an integrated pharmaceutical company incorporated in 2005 and headquartered in Panchkula, India, engages in research, development, manufacturing, distribution, and marketing of pharmaceutical products across India and internationally. The company operates three primary business segments: contract development and manufacturing organization (CDMO) services, which rank it as the second-largest domestic formulations CDMO and encompass over 2,400 products in diverse dosage forms including oral solids, oral liquids, dry syrups, injectables, modified and sustained release forms, and tablets-in-capsules for acute and chronic therapies; domestic branded generics marketed through a network of over 5,000 stockists and distributors reaching 150,000 Indian retailers, featuring therapeutic categories such as cephalosporins, proton pump inhibitors, anticholinergic and heparin NSAIDs, analgesics and antipyretics, anticold and antiallergics, antiemetics, antidiabetics, anticonvulsants and antipsychotics, bladder and prostate disorder treatments, antifungals, anthelmintics and antivirals, anticholinergics, anti-asthmatics, and bronchodilators in tablets, capsules, dry syrups, dry powder injections, ointments, and liquid orals; and international branded generics with over 200 products registered with authorities and presence in more than 15 countries. Recent major developments include the acquisition of Sharon Bio-Medicine Limited to bolster CDMO capabilities and regulated market exposure in regions such as Canada, the United Kingdom, Australia, and Central and South America; commissioning of a new greenfield manufacturing facility in Kathua, Jammu, achieving commercial operations by late 2024 with ongoing contributions to revenue; purchase of approximately 20 bighas of land in Baddi, Himachal Pradesh, for ₹19.5 crore in August 2025 to support future capacity expansion; and successful regulatory inspections at its cephalosporin plant in Baddi by the UK-MHRA and Jammu facility by Ukraine's State Service of Medicines and Drugs Control.